JP2016525563A5 - - Google Patents

Download PDF

Info

Publication number
JP2016525563A5
JP2016525563A5 JP2016530548A JP2016530548A JP2016525563A5 JP 2016525563 A5 JP2016525563 A5 JP 2016525563A5 JP 2016530548 A JP2016530548 A JP 2016530548A JP 2016530548 A JP2016530548 A JP 2016530548A JP 2016525563 A5 JP2016525563 A5 JP 2016525563A5
Authority
JP
Japan
Prior art keywords
carbon atoms
alkyl
therapeutic agent
halogen atom
diazepin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016530548A
Other languages
English (en)
Japanese (ja)
Other versions
JP6453877B2 (ja
JP2016525563A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/066629 external-priority patent/WO2015014998A1/en
Publication of JP2016525563A publication Critical patent/JP2016525563A/ja
Publication of JP2016525563A5 publication Critical patent/JP2016525563A5/ja
Application granted granted Critical
Publication of JP6453877B2 publication Critical patent/JP6453877B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016530548A 2013-08-01 2014-08-01 チエノトリアゾロジアゼピン化合物を含む医薬製剤 Expired - Fee Related JP6453877B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361861291P 2013-08-01 2013-08-01
US61/861,291 2013-08-01
US201361863118P 2013-08-07 2013-08-07
US61/863,118 2013-08-07
PCT/EP2014/066629 WO2015014998A1 (en) 2013-08-01 2014-08-01 Pharmaceutical formulation containing thienotriazolodiazepine compounds

Publications (3)

Publication Number Publication Date
JP2016525563A JP2016525563A (ja) 2016-08-25
JP2016525563A5 true JP2016525563A5 (https=) 2017-09-14
JP6453877B2 JP6453877B2 (ja) 2019-01-16

Family

ID=51260882

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016530548A Expired - Fee Related JP6453877B2 (ja) 2013-08-01 2014-08-01 チエノトリアゾロジアゼピン化合物を含む医薬製剤

Country Status (6)

Country Link
US (1) US9795612B2 (https=)
EP (1) EP3027194A1 (https=)
JP (1) JP6453877B2 (https=)
KR (1) KR20160036591A (https=)
CN (1) CN106029077A (https=)
WO (1) WO2015014998A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105960239A (zh) * 2013-11-27 2016-09-21 翁科埃斯克斯有限公司 利用含有噻吩并三唑并二氮杂*化合物的药物制剂治疗白血病的方法
CN107073014A (zh) * 2014-05-02 2017-08-18 翁科埃斯克斯有限公司 利用噻吩并三唑并二氮杂*化合物治疗急性髓细胞白血病和/或急性淋巴细胞性白血病的方法
CN107427524A (zh) * 2014-08-28 2017-12-01 翁科埃斯克斯有限公司 利用包含噻吩并三唑并二氮杂*化合物的药物组合物治疗急性髓细胞白血病或急性淋巴性白血病的方法
WO2016156905A1 (en) * 2015-04-03 2016-10-06 Oncoethix Gmbh Pharmaceutical doses for a bromodomain and extraterminal protein (bet) inhibitor
US10683305B2 (en) 2015-04-27 2020-06-16 Concert Pharmaceuticals, Inc. Deuterated OTX-015
CN110621305A (zh) * 2017-07-24 2019-12-27 爱科思华制药研发有限责任公司 高载药量药物组合物
KR20240028420A (ko) 2021-06-08 2024-03-05 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 항암 화합물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69717160T2 (de) * 1996-09-13 2003-05-08 Mitsubishi Pharma Corp., Osaka Thienotriazolodiazepinverbindungen und ihre medizinischen anwendungen
WO2001095912A1 (fr) * 2000-06-16 2001-12-20 Mitsubishi Pharma Corporation Compositions permettant de reguler la plage et/ou la vitesse de liberation du ph
EP1904654A2 (en) * 2005-07-15 2008-04-02 Brystol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mutant src kinase polypeptides
US20100120788A1 (en) * 2007-01-09 2010-05-13 Bristol-Myers Squibb Company Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in prostate cells
WO2009084693A1 (ja) * 2007-12-28 2009-07-09 Mitsubishi Tanabe Pharma Corporation 抗癌剤
CA2746220A1 (en) * 2008-12-08 2010-07-08 Vm Pharma Llc Compositions of protein receptor tyrosine kinase inhibitors
WO2011143651A1 (en) * 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating metabolism
MX354217B (es) * 2010-05-14 2018-02-19 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
AR084070A1 (es) * 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
US9249161B2 (en) 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
MX2014015986A (es) * 2012-06-25 2016-02-11 Oncoethix Gmbh Metodo para tratar linfoma utilizando compuestos de tienotriazolodiazepina.
CN104968334B (zh) * 2012-09-28 2018-09-14 翁科埃斯克斯有限公司 包含噻吩并三唑并二氮杂卓化合物的药物制剂
CN105960239A (zh) * 2013-11-27 2016-09-21 翁科埃斯克斯有限公司 利用含有噻吩并三唑并二氮杂*化合物的药物制剂治疗白血病的方法

Similar Documents

Publication Publication Date Title
JP2016525563A5 (https=)
JP2015531747A5 (https=)
JP2016529246A5 (https=)
JP2016538310A5 (https=)
JP2017517579A5 (https=)
RU2015101106A (ru) Способ лечения лимфомы, применяя тиенотриазолодиазепиновые соединения
JP2016523270A5 (https=)
JP2016507581A5 (https=)
RU2015133528A (ru) Замещенные полициклические пиразольные ингибиторы киназной активности и их применение
HRP20201985T1 (hr) Piridonski spoj kao c-met inhibitor
JP2013540712A5 (https=)
JP2021501208A5 (https=)
JP2010241830A5 (https=)
JP2014518544A5 (https=)
JP2017529332A5 (https=)
JP2019512535A5 (https=)
JP2016501185A5 (https=)
JP2011527667A5 (https=)
JP2014514317A5 (https=)
JP2015509536A5 (https=)
JP2016531868A5 (https=)
JP2017519727A5 (https=)
JP2015504091A5 (https=)
JP2017514909A5 (https=)
JP2015537017A5 (https=)